H.C. Wainwright reiterates a Buy rating on Solid Biosciences (SLDB) after Sarepta (SRPT) disclosed a second patient death due to acute liver failure following treatment with Elevidys. The news underscores the favorable safety profile of Solid’s SGT-003, the analyst tells investors in a research note. The firm believes SGT-003 has the most favorable safety profile among the leading Duchenne muscular dystrophy gene therapies either in clinic or in the market. Wainwright expects a meaningful share of ambulatory patients to transition from Elevidys to SGT-003.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Approves Equity Plan Amendment at Meeting
- Solid Biosciences reports inducement grants under Nasdaq listing rule
- Solid Biosciences Reports Increased Loss Amid R&D Expansion
- Solid Biosciences: Undervalued Gem with Promising Gene Therapy Pipeline and Upcoming Catalysts
- Solid Biosciences’ SGT-003 Therapy Shows Promise in DMD Treatment, Earning Buy Rating from Analyst
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue